Arvinas (ARVN) Competitors $7.32 +0.02 (+0.27%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.45 +0.13 (+1.78%) As of 08/22/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. HRMY, BLTE, SRPT, IRON, MESO, ARQT, CGON, ANIP, ADPT, and VCELShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Harmony Biosciences (HRMY), Belite Bio (BLTE), Sarepta Therapeutics (SRPT), Disc Medicine (IRON), Mesoblast (MESO), Arcutis Biotherapeutics (ARQT), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Adaptive Biotechnologies (ADPT), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors Harmony Biosciences Belite Bio Sarepta Therapeutics Disc Medicine Mesoblast Arcutis Biotherapeutics CG Oncology ANI Pharmaceuticals Adaptive Biotechnologies Vericel Harmony Biosciences (NASDAQ:HRMY) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has higher valuation & earnings, HRMY or ARVN? Harmony Biosciences has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarmony Biosciences$714.73M3.05$145.49M$3.1012.21Arvinas$263.40M2.04-$198.90M-$1.01-7.25 Does the media refer more to HRMY or ARVN? In the previous week, Harmony Biosciences had 7 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Harmony Biosciences and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.71 beat Harmony Biosciences' score of 1.53 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals have more ownership in HRMY or ARVN? 86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 23.6% of Harmony Biosciences shares are held by company insiders. Comparatively, 4.7% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate HRMY or ARVN? Harmony Biosciences presently has a consensus price target of $51.00, suggesting a potential upside of 34.71%. Arvinas has a consensus price target of $19.76, suggesting a potential upside of 169.99%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has more volatility and risk, HRMY or ARVN? Harmony Biosciences has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Is HRMY or ARVN more profitable? Harmony Biosciences has a net margin of 23.44% compared to Arvinas' net margin of -19.47%. Harmony Biosciences' return on equity of 26.34% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Harmony Biosciences23.44% 26.34% 17.71% Arvinas -19.47%-12.01%-6.97% SummaryHarmony Biosciences beats Arvinas on 12 of the 17 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$537.42M$3.12B$5.82B$9.78BDividend YieldN/A2.23%4.40%4.06%P/E Ratio-7.2521.0031.3026.05Price / Sales2.04356.92455.29117.98Price / CashN/A44.5038.0259.36Price / Book0.888.129.536.60Net Income-$198.90M-$54.72M$3.26B$265.65M7 Day Performance3.24%2.62%2.13%1.99%1 Month Performance-7.22%3.25%3.21%0.45%1 Year Performance-72.04%10.82%30.18%18.87% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas4.0811 of 5 stars$7.32+0.3%$19.76+170.0%-72.0%$537.42M$263.40M-7.25420Positive NewsHRMYHarmony Biosciences4.6655 of 5 stars$36.41-1.2%$51.00+40.1%+4.1%$2.09B$714.73M11.75200Positive NewsBLTEBelite Bio2.6218 of 5 stars$64.95-2.5%$96.67+48.8%+31.7%$2.07BN/A-41.9010SRPTSarepta Therapeutics4.5656 of 5 stars$20.99-3.8%$43.63+107.8%-85.6%$2.05B$2.48B-24.131,372Trending NewsAnalyst ForecastShort Interest ↑IRONDisc Medicine3.6995 of 5 stars$58.84-1.7%$96.18+63.5%+22.1%$2.05BN/A-13.1630Positive NewsMESOMesoblast2.0771 of 5 stars$15.93-2.0%$18.00+13.0%+141.0%$2.04B$5.90M0.0080News CoverageUpcoming EarningsARQTArcutis Biotherapeutics1.8009 of 5 stars$16.74-0.9%$19.80+18.3%+62.6%$2.01B$196.54M-22.32150News CoveragePositive NewsCGONCG Oncology1.3789 of 5 stars$26.13+1.7%$55.30+111.6%-27.3%$1.99B$1.14M-14.7661ANIPANI Pharmaceuticals3.1667 of 5 stars$89.71+2.6%$84.75-5.5%+47.6%$1.95B$747.40M-116.50600News CoverageAnalyst UpgradeInsider TradeADPTAdaptive Biotechnologies2.4124 of 5 stars$12.41-4.8%$12.38-0.3%+167.5%$1.89B$178.96M-15.13790News CoverageAnalyst RevisionVCELVericel2.4911 of 5 stars$36.32+0.1%$60.33+66.1%-24.9%$1.83B$249.12M302.69300Positive News Related Companies and Tools Related Companies HRMY Competitors BLTE Competitors SRPT Competitors IRON Competitors MESO Competitors ARQT Competitors CGON Competitors ANIP Competitors ADPT Competitors VCEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access